Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 2:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 16-Week Group Treatment Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Strength and Nutrition Outcomes for Latino Adolescents

NCT00697580
View directory record Official record
Conditions
Obesity, Type 2 Diabetes, Cardiovascular Risk, Cancer
Interventions
Nutrition, Strength Training & Nutrition, Circuit Training & Nutrition
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
14 Years to 18 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Sep 25, 2026, 2:45 PM EDT
Completed Phase 4 Interventional Results available

Interventions for Children With Attention and Reading Disorders

NCT01133847
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Reading Disabilities
Interventions
Methylphenidate, Intensive reading instruction, Parent Training, Mixed Salt Amphetamine, Atomoxetine, Guanfacine
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
7 Years to 12 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Sep 25, 2026, 2:45 PM EDT
Completed Not applicable Interventional

Multiple Sclerosis-Collaborative Approach to Rehabilitation Effectiveness Study

NCT02137044
View directory record Official record
Conditions
Multiple Sclerosis, Pain, Depression
Interventions
Collaborative Care (CC)
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Sep 25, 2026, 2:45 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis

NCT02905331
View directory record Official record
Conditions
Psoriasis
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Ocala, Florida • Rolling Meadows, Illinois • Plainfield, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 25, 2026, 2:45 PM EDT
Completed Phase 3 Interventional Results available

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)

NCT03160885
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
40
States / cities
Hot Springs, Arkansas • Encinitas, California • Fullerton, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 25, 2026, 2:45 PM EDT
Completed Phase 2 Interventional Results available

Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

NCT01055314
View directory record Official record
Conditions
Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma, Metastatic Childhood Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Untreated Childhood Rhabdomyosarcoma
Interventions
Cixutumumab, Cyclophosphamide, Dactinomycin, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Temozolomide, Vincristine Sulfate Liposome
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 49 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
121
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 100 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Sep 25, 2026, 2:45 PM EDT
Completed Phase 4 Interventional

Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial

NCT04708145
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Aflibercept Injection
Drug
Lead sponsor
Greater Houston Retina Research
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Beverly Hills, California • Orlando, Florida • Winter Haven, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Sep 25, 2026, 2:45 PM EDT
Completed Phase 1 Interventional

Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors

NCT00389922
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
lapatinib ditosylate, Vinorelbine ditartrate, comparative genomic hybridization, cytogenetic analysis, gene expression analysis, mutation analysis, polymerase chain reaction, polymorphism analysis, proteomic profiling, reverse transcriptase-polymerase chain reaction, immunohistochemistry staining method, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
4
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2012 · Synced Sep 25, 2026, 2:45 PM EDT
Completed Not applicable Interventional

Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors

NCT02235051
View directory record Official record
Conditions
Cancer Survivor, Estrogen Receptor-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Postmenopausal
Interventions
exercise intervention, laboratory biomarker analysis, questionnaire administration, quality-of-life assessment
Behavioral · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
56 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Sep 25, 2026, 2:45 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Alcohol and Bariatric Surgery

NCT02766322
View directory record Official record
Conditions
Obesity
Interventions
Oral Alcohol challenge test Alcohol visit first, Oral Alcohol challenge test Placebo visit first, Intravenous Alcohol Challenge Test (Clamp), Intravenous Alcohol Self-administration Test
Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
21 Years to 64 Years · Female only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 25, 2026, 2:45 PM EDT
Not listed Phase 1 Interventional

Project CORE: Disseminating Eating Disorders Treatment

NCT03855553
View directory record Official record
Conditions
Anorexia Nervosa/Bulimia, Anorexia Nervosa Restricting Type, Eating Disorders in Adolescence
Interventions
Family Based Treatment, Enhanced Cognitive Behavioral Therapy
Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
12 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 22, 2021 · Synced Sep 25, 2026, 2:45 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis

NCT04605094
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Benralizumab, Placebo / Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Los Angeles, California • Newport Beach, California • Bridgeport, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Sep 25, 2026, 2:45 PM EDT
Completed Not applicable Interventional

Mobile Mindfulness Meditation Intervention to Improve the Well-Being of Cancer Survivors

NCT03581357
View directory record Official record
Conditions
Cancer, Other Than Non-melanoma Skin Cancer
Interventions
Mobile Mindfulness Meditation, Mindfulness Coach
Behavioral
Lead sponsor
University of Hawaii
Other
Eligibility
21 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Palo Alto, California • Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Sep 25, 2026, 2:45 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability of Topical LFX453 for External Genital Warts

NCT02482428
View directory record Official record
Conditions
External Genital Warts
Interventions
Investigational Treatment, Aldara
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Arlington Heights, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 25, 2026, 2:45 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease

NCT03922711
View directory record Official record
Conditions
Parkinson Disease
Interventions
Pridopidine, Placebo
Drug
Lead sponsor
Prilenia
Industry
Eligibility
30 Years to 85 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Sep 25, 2026, 2:45 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

NCT03013998
View directory record Official record
Conditions
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
Biological · Other · Drug
Lead sponsor
Beat AML, LLC
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 25, 2026, 2:45 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis

NCT02438787
View directory record Official record
Conditions
Axial Spondyloarthritis
Interventions
Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg, Golimumab 50 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
19
States / cities
Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 25, 2026, 2:45 PM EDT
Completed Phase 2 Interventional Results available

Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus

NCT05188521
View directory record Official record
Conditions
Cutaneous Lichen Planus
Interventions
Baricitinib (LY3009104) 2 mg, Baricitinib (LY3009104) 4 mg
Drug
Lead sponsor
Aaron R. Mangold
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Sep 25, 2026, 2:45 PM EDT
Not listed Phase 2Phase 3 Interventional Results available

PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery

NCT01515787
View directory record Official record
Conditions
Colorectal Cancer
Interventions
FOLFOX (chemotherapy), 5 FUCMT (chemoradiation), surgery, magnetic resonance imaging or endorectal ultrasound
Drug · Other · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1048
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 613 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Sep 25, 2026, 2:45 PM EDT
Completed Phase 4 Interventional Results available

Combination Treatment Study for Memory Impairment and Depression

NCT01658228
View directory record Official record
Conditions
Depression, Mild Cognitive Impairment
Interventions
Donepezil, Placebo, Citalopram, Venlafaxine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
55 Years to 95 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Sep 25, 2026, 2:45 PM EDT
Completed Not applicable Interventional Results available

Transdiagnostic CBT for Comorbid Alcohol Use and Anxiety Disorders

NCT03230006
View directory record Official record
Conditions
Alcohol Use Disorder, Anxiety Disorders
Interventions
Unified Protocol for Transdiagnostic Treatment of Emotional Disorders, Take Control
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
21 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Sep 25, 2026, 2:45 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Pilot Factorial Trial of an Integrated Lifestyle Intervention

NCT06116435
View directory record Official record
Conditions
Physical Inactivity, Overweight and Obesity
Interventions
Prevent T2, Move group-based classes, Fitness Membership, Mental Imagery, Move 1:1 Support
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Sep 25, 2026, 2:45 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Multisite Implementation of COMPRENDO

NCT06055296
View directory record Official record
Conditions
Pediatric Cancer
Interventions
COMPRENDO Peer Navigation Intervention
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
4
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 25, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Results available

Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)

NCT00988559
View directory record Official record
Conditions
HPV16 Positive, Cervical Intraepithelial Neoplasia (CIN 2/3)
Interventions
DNA vaccination, Gene gun vaccine, intramuscular vaccination, intra-lesional vaccine administration, therapeutic resection of the lesion, imiquimod
Biological · Device · Procedure + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
3
States / cities
Birmingham, Alabama • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 8, 2018 · Synced Sep 25, 2026, 2:45 PM EDT